Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on January 11, 2016, reporting key operational metrics for the full year ended December 31, 2015. The company specializes in the Argus II Retinal Prosthesis System.
Key Financial and Operational Metrics
The filing focuses on operational performance rather than financial statements. Key metrics for 2015 include:
- Total Implants: 75 Argus II systems implanted worldwide in 2015.
- Q4 2015 Implants: 21 systems.
- Implanting Centers: 33 centers worldwide at year-end (up from 18 in 2014).
- Clinical Trials: 4 of 5 planned subjects successfully implanted in the Dry Age-Related Macular Degeneration (AMD) trial in the U.K.
- Reimbursement: Medicare coverage expanded to 16 states.
Note: The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes Versus Prior Period
Comparing 2015 to 2014, the company reported significant growth in implant volume and infrastructure:
- Annual Implant Growth: Total implants increased from 29 in 2014 to 75 in 2015, representing a 159% increase.
- Quarterly Implant Growth: Q4 2015 implants (21) increased from Q4 2014 implants (15), representing a 40% increase.
- Center Expansion: The number of implanting centers nearly doubled, growing from 18 at the end of 2014 to 33 at the end of 2015.
Outlook, Risks, and Management Commentary
Management highlighted successful expansion of the commercial footprint and clinical progress. The addition of two new implanting centers in Q4 2015 and the expansion of Medicare coverage by 10 states were cited as key drivers for future volume. The filing incorporates a press release by reference but does not contain explicit forward-looking guidance, risk factors, or discussion of unusual items within the text provided.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed financial results not included in this summary.
- Confirm the specific states where Medicare coverage was expanded to assess market penetration.
- Review the status of the remaining subject in the Dry AMD clinical trial in the U.K.
- Check subsequent filings for Q4 2015 and full-year 2015 revenue and cash flow data.